{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:03:00Z","timestamp":1789686180492,"version":"4.0.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>: Familial combined hyperlipidemia (FCH), defined by concurrently elevated plasma triglyceride (TG) and low-density lipoprotein (LDL) cholesterol, has long been investigated to characterize its genetic basis. Despite almost half a century of searching, a single gene cause for the phenotype has not yet been identified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>: Recent studies using next-generation genetic analytic methods confirm that FCH has a polygenic basis, with a clear large contribution from the accumulation of small-to-moderate effect common single nucleotide polymorphisms (SNPs) throughout the genome that is associated with raising TG, and probably also those raising LDL cholesterol. On the other hand, rare monogenic variants, such as those causing familial hypercholesterolemia, play a negligible role, if any. Genetic profiling suggests that patients with FCH and hypertriglyceridemia share a strong polygenic basis and show a similar profile of multiple TG-raising common SNPs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>: Recent progress in genomics has shown that most if not all of the genetic susceptibility to FCH is polygenic in nature. Future research should include larger cohort studies, with wider ancestral diversity, ancestry-specific polygenic scores, and investigation of epigenetic and lifestyle factors to help further elucidate the causative agents at play in cases where the genetic etiology remains to be defined.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000796","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T04:02:19Z","timestamp":1635134539000},"page":"126-132","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Familial combined hyperlipidemia is a polygenic trait"],"prefix":"10.1097","volume":"33","author":[{"given":"Praneet K.","family":"Gill","sequence":"first","affiliation":[{"name":"Robarts Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[{"name":"Robarts Research Institute"},{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"R1-20250729","first-page":"1362","article-title":"Pediatric dyslipidemia\u2014beyond familial hypercholesterolemia","volume":"36","author":"Lazarte","year":"2020","journal-title":"Can J Cardiol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.mol.0000226121.27931.3f","article-title":"Genetics of familial combined hyperlipidemia","volume":"17","author":"Naukkarinen","year":"2006","journal-title":"Curr Opin Lipidol"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in Coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J Clin Investig"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2004-835379","article-title":"Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis","volume":"4","author":"Aguilar Salinas","year":"2004","journal-title":"Semin Vasc Med"},{"key":"R5-20250729","first-page":"224","article-title":"Familial combined hyperlipidemia: current knowledge, perspectives, and controversies","volume":"70","author":"Bello-Chavolla","year":"2018","journal-title":"Rev Investig Clin"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/iub.2073","article-title":"Familial combined hyperlipidemia: an overview of the underlying molecular mechanisms and therapeutic strategies","volume":"71","author":"Taghizadeh","year":"2019","journal-title":"IUBMB Life"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11883-021-00939-y","article-title":"The genetic basis of hypertriglyceridemia","volume":"23","author":"Carrasquilla","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cca.2018.09.009","article-title":"Metabolic disorders and inflammation are associated with familial combined hyperlipemia","volume":"490","author":"D\u00edaz-Ruiz","year":"2019","journal-title":"Clin Chim Acta"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1172\/JCI107333","article-title":"Hyperlipidemia in Coronary Heart Disease III. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction","volume":"52","author":"Hazzard","year":"1973","journal-title":"J Clin Investig"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MOL.0000000000000270","article-title":"Combined hyperlipidemia: familial but not (usually) monogenic","volume":"27","author":"Brahm","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diab Endocrinol"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"e002725","DOI":"10.1161\/CIRCGEN.119.002725","article-title":"Polygenic hyperlipidemias and coronary artery disease risk","volume":"13","author":"Ripatti","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/07853890600865759","article-title":"Unraveling the complex genetics of familial combined hyperlipidemia","volume":"38","author":"Suviolahti","year":"2006","journal-title":"Ann Med"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jacl.2020.11.006","article-title":"Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia","volume":"15","author":"Gill","year":"2021","journal-title":"J Clin Lipidol"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/CIRCGENETICS.114.000522","article-title":"Common genetic variants contribute to primary hypertriglyceridemia without differences between familial combined hyperlipidemia and isolated hypertriglyceridemia","volume":"7","author":"De Castro-Or\u00f3s","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mcp.2014.10.002","article-title":"Association of USF1 and APOA5 polymorphisms with familial combined hyperlipidemia in an Italian population","volume":"29","author":"Di Taranto","year":"2015","journal-title":"Mol Cell Probes"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/ATVBAHA.107.151530","article-title":"USF1 Contributes to high serum lipid levels in dutch FCHL families and u.s. whites with coronary artery disease","volume":"27","author":"Lee","year":"2007","journal-title":"Arterioscler Thromb Basc Biol"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1253\/circj.70.1606","article-title":"Apolipoprotein E polymorphism influences lipid phenotypes in chinese families with familial combined hyperlipidemia","volume":"70","author":"Pei","year":"2006","journal-title":"Circ J"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"e1006078","DOI":"10.1371\/journal.pgen.1006078","article-title":"The contribution of GWAS loci in familial dyslipidemias","volume":"12","author":"Ripatti","year":"2016","journal-title":"PLoS Genet"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jacc.2008.06.050","article-title":"Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting","volume":"52","author":"Civeira","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"102313","DOI":"10.1016\/j.scr.2021.102313","article-title":"A nonintegrated iPSC line (SDQLCHi042-A) from a boy suffering from familial combined hyperlipidemia with compound heterozygous mutations of lipoprotein lipase gene","volume":"53","author":"Li","year":"2021","journal-title":"Stem Cell Res"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/biof.1570","article-title":"A novel variant in LPL gene is associated with familial combined hyperlipidemia","volume":"46","author":"Taghizadeh","year":"2020","journal-title":"Biofactors"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.ATV.17.5.841","article-title":"No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in finnish families","volume":"17","author":"Pajukanta","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/hmg\/ddi294","article-title":"USF1 and dyslipidemias: converging evidence for a functional intronic variant","volume":"14","author":"Naukkarinen","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng1320","article-title":"Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1)","volume":"36","author":"Pajukanta","year":"2004","journal-title":"Nat Genet"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1194\/jlr.M600184-JLR200","article-title":"The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemia","volume":"48","author":"van der Vleuten","year":"2007","journal-title":"J Lipid Res"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/iub.2186","article-title":"A novel mutation in USF1 gene is associated with familial combined hyperlipidemia","volume":"72","author":"Taghizadeh","year":"2020","journal-title":"IUBMB Life"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCGENETICS.108.840421","article-title":"Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias","volume":"2","author":"Naukkarinen","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1161\/ATVBAHA.112.245639","article-title":"Potential role of upstream stimulatory factor 1 gene variant in familial combined hyperlipidemia and related disorders","volume":"32","author":"Auer","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1038\/s41598-021-86384-y","article-title":"ANGPTL3 gene variants in subjects with familial combined hyperlipidemia","volume":"11","author":"Bea","year":"2021","journal-title":"Sci Rep"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2021.05.007","article-title":"APOE gene variants in primary dyslipidemia","volume":"328","author":"Khalil","year":"2021","journal-title":"Atherosclerosis"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2012.03.011","article-title":"Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia","volume":"222","author":"Solanas-Barca","year":"2012","journal-title":"Atherosclerosis"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/humu.22215","article-title":"Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation","volume":"34","author":"Marduel","year":"2013","journal-title":"Hum Mutat"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.3892\/mmr.2015.3263","article-title":"Identification of the differentially expressed genes associated with familial combined hyperlipidemia using bioinformatics analysis","volume":"11","author":"Luo","year":"2015","journal-title":"Mol Med Rep"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"28-34.e2","DOI":"10.1016\/j.jacl.2020.01.003","article-title":"The polygenic nature of mild-to-moderate hypertriglyceridemia","volume":"14","author":"Dron","year":"2020","journal-title":"J Clin Lipidol"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/ATVBAHA.111.226365","article-title":"An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia","volume":"31","author":"Johansen","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.atherosclerosis.2015.06.036","article-title":"Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach","volume":"242","author":"Minicocci","year":"2015","journal-title":"Atherosclerosis"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.11.013","article-title":"Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study","volume":"280","author":"Luijten","year":"2019","journal-title":"Atherosclerosis"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11745-015-4005-0","article-title":"Rosuvastatin enhances the catabolism of LDL apoB-100 in subjects with combined hyperlipidemia in a dose dependent manner","volume":"50","author":"Le","year":"2015","journal-title":"Lipids"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2710.2008.01004.x","article-title":"Efficacy and safety of ezetimibe\/simvastatin association on nondiabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment","volume":"34","author":"Derosa","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10557-016-6666-1","article-title":"Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia","volume":"30","author":"Rosenson","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/HCO.0000000000000839","article-title":"Genetics of hypertriglyceridemia and atherosclerosis","volume":"36","author":"Gill","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3945\/jn.114.191775","article-title":"Serum lipid responses to weight loss differ between overweight adults with familial hypercholesterolemia and those with familial combined hyperlipidemia","volume":"144","author":"Mateo-Gallego","year":"2014","journal-title":"J Nutr"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.amjcard.2012.06.050","article-title":"Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia","volume":"110","author":"Guo","year":"2012","journal-title":"Am J Cardiol"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MOL.0000000000000387","article-title":"Does lifestyle contribute to disease severity in patients with inherited lipid disorders?","volume":"28","author":"Arsenault","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"R47-20250729","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pathol.2018.11.006","article-title":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment","volume":"51","author":"Carr","year":"2019","journal-title":"Pathology"},{"key":"R48-20250729","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11886-020-01323-z","article-title":"Non-HDL cholesterol or apoB: which to prefer as a target for the prevention of atherosclerotic cardiovascular disease?","volume":"22","author":"Langlois","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"323ra13","DOI":"10.1126\/scitranslmed.aad0015","article-title":"USF1 deficiency activates brown adipose tissue and improves cardiometabolic health","volume":"8","author":"Laurila","year":"2016","journal-title":"Sci Transl Med"},{"key":"R50-20250729","doi-asserted-by":"crossref","first-page":"e1000642","DOI":"10.1371\/journal.pgen.1000642","article-title":"A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia","volume":"5","author":"Plaisier","year":"2009","journal-title":"PLoS Genet"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:07:17Z","timestamp":1753826837000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000796","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}